Fabrizio Chegai

Fabrizio Chegai

Auto-generated profile, based on publicly available information

Fabrizio Chegai

Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University Hospital Tor Vergata, Rome, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
AOAntonio Orlacchio
Antonio Orlacchio
FCFabrizio Chegai
Fabrizio Chegai
CGCostantino Del Giudice
Costantino Del Giudice
AAAlessandro Anselmo
Alessandro Anselmo
GIGiuseppe Iaria
Giuseppe Iaria
GSGiovanni Simonetti
Giovanni Simonetti

1 January 2016 in Journal of Cancer
Verified
Journal Article
Open access
JGJill S Gluskin
Jill S Gluskin
FCFabrizio Chegai
Fabrizio Chegai
Serena MontiSerena Monti
Serena Monti
ESEttore Squillaci
Ettore Squillaci
LMLorenzo Mannelli
Lorenzo Mannelli
Differentiating between cancerous tissue and healthy liver parenchyma could represent a challenge with the only conventional Magnetic Resonance (MR) imaging. Diffusion weighted imaging (DWI) exploits different tissue characteristics to conventional Magnetic Resonance Imaging (MRI) sequences that enhance hepatocellular carcinoma (HCC) detection, characterization, and post-treatment evaluation. Detection of HCC is improved by DWI, infact this technology increases conspicuity of lesions that might otherwise not be identified due to obscuration by adjacent vessels or due to low contrast between the lesion and background liver. It is important to remember that DWI combined with contrast-enhanced MRI has higher sensitivity than DWI alone, and that some patients are not eligible for use of contrast on CT and MRI; in these patients DWI has a prominent role. MRI has advanced beyond structural anatomic imaging to now showing pathophysiologic processes. DWI is a promising way to characterize lesions utilizing the inherent contrast within the liver and has the benefit of not requiring contrast injection. DWI improves detection and characterization of HCC. Proposed clinical uses for DWI include: assessing prognosis, predicting response, monitoring response to therapy, and distinguishing tumor recurrence from treatment effect. Ideally, DWI will help risk stratify patients and will participate in prognostic modeling.

18 February 2014 in Prostate Cancer
Verified
Journal Article
Open access
PDF file
GMGuglielmo Manenti
Guglielmo Manenti
MNMarco Nezzo
Marco Nezzo
FCFabrizio Chegai
Fabrizio Chegai
EVErald Vasili
Erald Vasili
EBElena Bonanno
Elena Bonanno
GSGiovanni Simonetti
Giovanni Simonetti
Aim. To compare the diagnostic performance of diffusion weighted imaging (DWI) usingb-values of 1000 s/mm2and 2000 s/mm2at 3 Tesla (T) for the evaluation of clinically significant prostate cancer.Matherials and Methods. Seventy-eight prostate cancer patients underwent a 3T MRI scan followed by radical prostatectomy. DWI was performed usingb-values of 0, 1000, and 2000 s/mm2and qualitatively analysed by two radiologists. ADC maps were obtained atb-values of 1000 and 2000 s/mm2and quantitatively analyzed in consensus.Results. For diagnosis of 78 prostate cancers the accuracy of DWI for the young reader was significantly greater atb= 2000 s/mm2for the peripheral zone (PZ) but not for the transitional zone (TZ). For the experienced reader, DWI did not show significant differences in accuracy betweenb-values of 1000 and 2000 s/mm2. The quantitative analysis in the PZ and TZ was substantially superimposable between the twob-values, albeit with a higher accuracy with ab-value of 2000 s/mm2.Conclusions. With ab-value of 2000 s/mm2at 3T both readers differentiated clinical significant cancer from benign tissue; higherb-values can be helpful for the less experienced readers.

1 January 2015 in World Journal of Hepatology
Verified
Journal Article
Open access
AOAntonio Orlacchio
Antonio Orlacchio
FCFabrizio Chegai
Fabrizio Chegai
SMStefano Merolla
Stefano Merolla
SFSimona Francioso
Simona Francioso
CGCostantino Del Giudice
Costantino Del Giudice
GSGiovanni Simonetti
Giovanni Simonetti
Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization

26 November 2013 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
AOAntonio Orlacchio
Antonio Orlacchio
FBFrancesca Bolacchi
Francesca Bolacchi
FCFabrizio Chegai
Fabrizio Chegai
ABAlberto Bergamini
Alberto Bergamini
ECElisa Costanzo
Elisa Costanzo
GSGiovanni Simonetti
Giovanni Simonetti

1 October 2015 in Hepatic Oncology
Verified
Journal Article
Open access
FCFabrizio Chegai
Fabrizio Chegai
AOAntonio Orlacchio
Antonio Orlacchio
SMStefano Merolla
Stefano Merolla
Serena MontiSerena Monti
Serena Monti
LMLorenzo Mannelli
Lorenzo Mannelli
According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients ...